Cowen Reiterates Outperform Rating on Allogene (ALLO), "We Recommend Accumulating ALLO Shares"

February 24, 2022 5:31 AM EST
Get Alerts ALLO Hot Sheet
Price: $7.47 -3.24%

Rating Summary:
    17 Buy, 3 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 27 | New: 29
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Cowen analyst Tyler Van Buren reiterated an Outperform rating on Allogene (NASDAQ: ALLO), following resumption of the company's AlloCAR T studies.

The analyst quotes: "All AlloCAR T studies have resumed and Allogene has plenty of cash ($810MM). The pivotal ALPHA2 ALLO-501A trial is on track to commence mid-year with a registrational ALLO-647 trial that will be conducted in parallel and should be informative. Clinical study activities for ALLO-715, ALLO-605, and ALLO-316 have also resumed with a BCMA update expected by YE. We recommend accumulating ALLO shares."

For an analyst ratings summary and ratings history on Allogene click here. For more ratings news on Allogene click here.

Shares of Allogene closed at $9.17 yesterday.

By Vlad Schepkov | [email protected]

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Cowen & Co, Vlad Schepkov